MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
The first publication of clinical data for YL201,featured in an oral presentation at ESMO 2024. Encouraging antitumor activity of YL201 in multiple solid tumor types,including SCLC,NPC,and wild-type